echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The first imitation base drug of Ivabradine tablets has been approved for marketing!

    The first imitation base drug of Ivabradine tablets has been approved for marketing!

    • Last Update: 2021-06-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 25, 2021, CDE data showed that the ivabradine hydrochloride tablets (National Medicines Standard H20213404) declared by Beijing Baiao Pharmaceutical Co.


    According to the "China Cardiovascular Disease Report 2018" data, cardiovascular disease is the leading cause of death for Chinese residents.


    The mortality and rehospitalization rates of patients with heart failure within 2 to 3 months after discharge are as high as 15% and 30%.


    Ivabradine was originally made into tablets in the form of hydrochloride.


    The so-called essential medicine is a concept put forward by the World Health Organization (WHO) in 1977.


    On March 1, 2021, the National Health Commission convened the 2021 National Pharmaceutical Administration Video and Telephone Conference.


    At present, only ivabradine hydrochloride tablets from the original research manufacturer Servier are on the market in China.


    At the same time, data from Meinenet showed that the sales of ivabradine hydrochloride tablets in China's public medical institutions increased by 705.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.